PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer
This study highlights the immune system-activating properties of PARP inhibitors and suggests harnessing these for effective PARPi therapy in ovarian cancer, especially in the context of HRP disease.
Authors
- D Hamann
- M Riedel (ORCID: https://orcid.org/0000-0002-9524-1514)
- Holger Bronger (ORCID: https://orcid.org/0000-0002-3706-6738)
- Marion B. Kiechle (ORCID: https://orcid.org/0000-0003-4237-2657)
- Christoph Stange (ORCID: https://orcid.org/0000-0002-9663-3472)
- Tobias F. Dreyer (ORCID: https://orcid.org/0000-0002-5366-7859)
- Stefanie Seitz
- Franziska Elsen
Institutions
- German Cancer Research Center (DE)
- Technical University of Munich (DE)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1038/s41416-025-03076-4
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wilhelm Sander-Stiftung
- Deutsche Forschungsgemeinschaft